RANK ligand as a therapeutic target for bone metastases and multiple myeloma

G. David Roodman, William C. Dougall

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL.

Original languageEnglish (US)
Pages (from-to)92-101
Number of pages10
JournalCancer Treatment Reviews
Volume34
Issue number1
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

RANK Ligand
Multiple Myeloma
Neoplasm Metastasis
Bone and Bones
Bone Diseases
Neoplasms
Bone Resorption
Osteogenesis
Receptor Activator of Nuclear Factor-kappa B
Therapeutics
Spinal Cord Compression
Tropism
Bone Fractures
Hypercalcemia
Bone Marrow
Pain
Pharmaceutical Preparations

Keywords

  • Bone metastasis
  • Breast cancer
  • Multiple myeloma
  • OPG
  • Osteoclast
  • Prostate cancer
  • RANK
  • RANKL
  • Skeletal complications

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

RANK ligand as a therapeutic target for bone metastases and multiple myeloma. / Roodman, G. David; Dougall, William C.

In: Cancer Treatment Reviews, Vol. 34, No. 1, 02.2008, p. 92-101.

Research output: Contribution to journalArticle

@article{c146c33d03f24fa78259558c51513412,
title = "RANK ligand as a therapeutic target for bone metastases and multiple myeloma",
abstract = "Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL.",
keywords = "Bone metastasis, Breast cancer, Multiple myeloma, OPG, Osteoclast, Prostate cancer, RANK, RANKL, Skeletal complications",
author = "Roodman, {G. David} and Dougall, {William C.}",
year = "2008",
month = "2",
doi = "10.1016/j.ctrv.2007.09.002",
language = "English (US)",
volume = "34",
pages = "92--101",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - RANK ligand as a therapeutic target for bone metastases and multiple myeloma

AU - Roodman, G. David

AU - Dougall, William C.

PY - 2008/2

Y1 - 2008/2

N2 - Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL.

AB - Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL.

KW - Bone metastasis

KW - Breast cancer

KW - Multiple myeloma

KW - OPG

KW - Osteoclast

KW - Prostate cancer

KW - RANK

KW - RANKL

KW - Skeletal complications

UR - http://www.scopus.com/inward/record.url?scp=38749106994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749106994&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2007.09.002

DO - 10.1016/j.ctrv.2007.09.002

M3 - Article

C2 - 17964729

AN - SCOPUS:38749106994

VL - 34

SP - 92

EP - 101

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 1

ER -